124499-35-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetonitrile is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex organic molecules and bioactive compounds.
Used in Organic Synthesis:
2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetonitrile is used as a building block in organic synthesis for its potential to form other compounds, particularly due to its acetonitrile functional group.
Used in Chemical Industry:
2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetonitrile is used as a valuable intermediate in the chemical industry for its diverse applications in the synthesis of complex organic molecules.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 2537-48-6 diethyl 1-cyanomethylphosphonate 

Downstream Products

• 143366-39-6 4-(2-Oxo-2-phenyl-ethyl)-cyclohexanone 
• 143366-40-9 4-(2-Oxo-hexyl)-cyclohexanone 
• 86428-59-3 4-(2-oxopropyl)cyclohexan-1-one 
• 124499-37-2 1,4-dioxaspiro[4.5]dec-8-yl acetonitrile 

Relevant academic research and scientific papers

Beyond Chemoselectivity: Catalytic Site-Selective Aldolization of Diketones and Exploitation for Enantioselective Alzheimer's Drug Candidate Synthesis

Site selectivity, differentiating instances of the same functional group type on one substrate, represents a forward-looking theme within chemistry: reduced dependence on protection/deprotection protocols for increased overall yield and step-efficiency. Despite these potential benefits and the expanded tactical advantages afforded to synthetic design, site selectivity remains elusive and especially so for ketone-based substrates. Herein, site-selective intermolecular mono-aldolization has been demonstrated for an array of prochiral 4-keto-substituted cyclohexanones with concomitant regio-, diastereo-, and enantiocontrol. Importantly, the aldol products allow rapid access to molecularly complex ketolactones or keto-1,3-diols, respectively containing three and four stereogenic centers. The reaction conditions are of immediate practical value and general enough to be applicable to other reaction types. These findings are applied in the first enantioselective, formal, synthesis of a leading Alzheimer's research drug, a γ-secretase modulator (GSM), in the highest known yield.

GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors

Discovery and optimization of a piperidyl benzamide series of 11β-HSD1 inhibitors is described. This series was derived from a cyclohexyl benzamide lead structures to address PXR selectivity, high non-specific protein binding, poor solubility, limited in

Sulphonamide derivatives

The present invention provides novel sulphonamide derivatives which are useful for potentiating glutamate receptor function in a mammal requiring treatment, processes for their preparation, and pharmaceutical compositions containing them.

Synthesis of 3- and 4-Substituted Cyclic α-Amino Acids Structurally Related to ACPD

The preparation of 3-substituted cyclopentanones 12-16, 4-substituted cyclohexanones 23-28 and cycloheptanones 38-41 is described.Substituents in the cycloalkanones are carboxylate, phosphonate or tetrazole groups, separated from the ring by a 0, 1, 2, or 3 carbon atoms chain.These cycloalkanones have been transformed into α-amino acids 9-11 by hydrolysis of the corresponding hydantoin derivatives 21, 37 and 62, obtained under Bucherer-Bergs reaction conditions.

Drastic ring transformation reactions of fused bicyclic rings to bridged bicyclic rings

By treatment with BF3-etheratelethylene glycol, cyclohexanone with a carbonyl function at the 2′-(or 3′-) position of γ-side chain underwent novel ring transformation to afford five- (or six-) membered rings, and the fused bicyclic rings (bicyc

2-(SUBSTITUTED AMINO) ADENOSINES AS ANTIHYPERTENSIVES

Disclosed are 2-substituted adenosine derivatives of the formula STR1 in which R represents a substituted amino grouping of the formula STR2 as defined herein; pharmaceutically acceptable ester derivatives thereof in which free hydroxy groups are esterified in the form of a pharmaceutically acceptable prodrug ester; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for their preparation; and their use in mammals as therapeutically effective adenosine-2 (A-2) agonists.